ARS Pharmaceuticals Inc — Cash Flow (NASDAQ:SPRY) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Cash from operating activities -66.76 M-40.08 M-59.27 M13.55 M-170.87 M -170.87 M Cash from investing activities -66.48 M-199 K-87.18 M-106.1 M56.77 M 56.77 M Cash from financing activities 614 K190.73 M6.9 M72.4 M104.6 M 104.6 M Free cash flow -68.13 M-40.28 M-59.44 M12.98 M-171.21 M -171.21 M

Haberler

Kanada şiddetli alerjiler için neffy burun spreyini onayladı

Northland, ARS Pharmaceuticals hissesine alım tavsiyesi verdi

William Blair, FDA etiket güncellemesi sonrası ARS Pharma hissesinde Outperform görüşünü koruyor

ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY)

Leerink raises ARS Pharmaceuticals stock price target on sales expansion

ARS Pharmaceuticals 4Ç 2025 tahminlerini aştı, hisse yükseldi

Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises

ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript

ARS Pharmaceuticals kazancı $0,01 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek

ARS Pharmaceuticals earnings beat by $0.01, revenue topped estimates

ARS Pharmaceuticals, Inc. (SPRY) Reports Q4 Loss, Beats Revenue Estimates

Canadian Natural to Report Q4 Earnings: What's in the Offing?